Learn More
Avalyn to Participate in Multiple Upcoming Investor Conferences in November
Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
Avalyn to Participate in the Jefferies Global Healthcare Conference in June
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
Avalyn to Participate in Upcoming Investor Conference in April
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
Avalyn to Participate in TD Cowen 45th Annual Health Care Conference
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Avalyn to Participate in Multiple Upcoming Investor Conferences
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
Load MoreShow Less
